This is mainly a sequencing-risk equity. The opportunity is real, but the biggest value unlocks arrive only if
Neutron proves out on schedule, defense demand keeps broadening beyond one-off awards, and the Iridium deal closes without an ugly capital structure. If those gates slip, Rocket Lab can still grow operationally while the stock de-rates.